Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Swedes Explain Why They Should Have the EMA ‘Gem’ After Brexit

Executive Summary

Sweden explains the reasons why the European Medicines Agency should move there from London once the UK leaves the EU, citing an established life sciences network, a strong R&D sector, and a solid biopharmaceutical industry base.


Related Content

Race Hots Up For EMA After Brexit
‘Virtually Bribery And Corruption Free’ Denmark With Its Clean Canals Says ‘Give Us EMA’
EMA Post-Brexit: 'It Can’t Stay In The UK' … Or Can It?
Dublin The Odds: Ireland Plays On Strengths As It Prepares EMA Bid





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts